Alnylam Pharmaceuticals Target Price

See Alnylam Pharmaceuticals's analyst price targets ($370) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$254.07

Average Target Price

$368.39

45% upside

18 analysts in the last 4 months

High: $485 | Low: $230

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-09-08	Jefferies	$260	2.3% upside
2026-08-28	Jefferies	$230	9.5% downside
2026-08-25	BernsteinJeffrey Walch	$376	48% upside
2026-08-18	BMO Capital	$318	25.2% upside
2026-08-14	Wells FargoDerek Archila	$256	0.8% upside
2026-08-04	H.C. Wainwright	$455	79.1% upside
2026-08-04	Truist Financial	$315	24% upside
2026-08-03	BarclaysEliana Merle	$450	77.1% upside
2026-07-31	Raymond JamesMartin Auster	$420	65.3% upside
2026-07-31	RBC CapitalLuca Issi	$350	37.8% upside
2026-07-31	Oppenheimer	$350	37.8% upside
2026-07-31	Morgan Stanley	$300	18.1% upside
2026-07-31	Stifel NicolausPaul Matteis	$318	25.2% upside
2026-07-13	H.C. Wainwright	$485	90.9% upside
2026-07-13	Truist Financial	$410	61.4% upside
2026-07-10	Morgan Stanley	$400	57.4% upside
2026-07-09	Raymond James	$468	84.2% upside
2026-06-29	H.C. Wainwright	$470	85% upside
2026-05-01	Morgan Stanley	$370	45.6% upside
2026-05-01	Bernstein	$447	75.9% upside
2026-02-17	Canaccord Genuity	$429	68.9% upside
2026-02-13	Morgan Stanley	$360	41.7% upside
2026-02-13	Bernstein	$451	77.5% upside
2026-02-13	Chardan Capital	$425	67.3% upside
2026-02-12	Stifel NicolausPaul Matteis	$444	74.8% upside
2026-01-30	H.C. Wainwright	$510	100.7% upside
2026-01-20	RBC Capital	$465	83% upside
2026-01-20	Wells Fargo	$376	48% upside
2026-01-12	Needham	$529	108.2% upside
2026-01-12	Raymond JamesMartin Auster	$472	85.8% upside
2026-01-08	Truist Financial	$530	108.6% upside
2026-01-06	Bernstein	$491	93.3% upside
2025-12-15	Leerink PartnersMani Foroohar	$351	38.2% upside
2025-12-11	Stifel Nicolaus	$508	99.9% upside
2025-11-04	H.C. WainwrightPatrick Trucchio	$570	124.3% upside
2025-10-31	Barclays	$527	107.4% upside
2025-10-31	OppenheimerLeland Gershell	$500	96.8% upside
2025-10-31	Chardan CapitalKeay Nakae	$475	87% upside
2025-10-30	UBS	$549	116.1% upside
2025-10-30	Morgan StanleyMichael Ulz	$495	94.8% upside
2025-10-22	Cantor Fitzgerald	$450	77.1% upside
2025-10-17	Truist Financial	$535	110.6% upside
2025-10-06	Morgan StanleyMichael Ulz	$475	87% upside
2025-10-06	Stifel NicolausPaul Matteis	$495	94.8% upside
2025-09-05	BMO CapitalKostas Biliouris	$470	85% upside
2025-07-29	Raymond James	$370	45.6% upside
2025-07-21	Truist FinancialDanielle Brill	$385	51.5% upside
2025-06-24	BMO CapitalKostas Biliouris	$360	41.7% upside
2025-03-21	Scotiabank	$338	33% upside
2025-01-07	BernsteinWilliam Pickering	$310	22% upside

Alnylam Pharmaceuticals (ALNY) FAQ

Alnylam Pharmaceuticals (ALNY) currently reports a target price of $370. Use the charts on this page to explore Alnylam Pharmaceuticals's target price history and peer comparisons.

Analysts' average 12-month price target for Alnylam Pharmaceuticals is $370, about 45.0% upside from the current share price of $254.07. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $370, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Alnylam Pharmaceuticals, and consider following ALNY for alerts when major investors trade the stock.

Alnylam Pharmaceuticals is classified in the Healthcare sector. On target price, it currently shows $370. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ALNY with unrelated industries.